Ranjit Nair

2.9k total citations
97 papers, 723 citations indexed

About

Ranjit Nair is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Ranjit Nair has authored 97 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 50 papers in Pathology and Forensic Medicine and 26 papers in Genetics. Recurrent topics in Ranjit Nair's work include Lymphoma Diagnosis and Treatment (48 papers), CAR-T cell therapy research (43 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Ranjit Nair is often cited by papers focused on Lymphoma Diagnosis and Treatment (48 papers), CAR-T cell therapy research (43 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Ranjit Nair collaborates with scholars based in United States, South Korea and India. Ranjit Nair's co-authors include Sattva S. Neelapu, Jason R. Westin, Sairah Ahmed, Paolo Strati, Loretta J. Nastoupil, Maria Alma Rodriguez, Raphaël Steiner, Swaminathan P. Iyer, Hun Ju Lee and Misha Hawkins and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ranjit Nair

79 papers receiving 718 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ranjit Nair United States 13 594 269 113 110 109 97 723
Zhitao Ying China 14 502 0.8× 382 1.4× 171 1.5× 74 0.7× 72 0.7× 73 797
Gloria Iacoboni Spain 16 588 1.0× 294 1.1× 111 1.0× 120 1.1× 103 0.9× 65 730
Hien Liu United States 11 449 0.8× 153 0.6× 67 0.6× 118 1.1× 91 0.8× 62 594
Chaitra S. Ujjani United States 15 622 1.0× 487 1.8× 156 1.4× 63 0.6× 76 0.7× 92 855
Shinichi Makita Japan 16 403 0.7× 413 1.5× 143 1.3× 41 0.4× 51 0.5× 78 719
Alison R. Sehgal United States 13 633 1.1× 174 0.6× 227 2.0× 126 1.1× 136 1.2× 52 1.1k
Houston Holmes United States 12 319 0.5× 146 0.5× 119 1.1× 32 0.3× 69 0.6× 39 540
Quanshun Wang China 10 755 1.3× 142 0.5× 245 2.2× 83 0.8× 241 2.2× 63 1.0k
N. Nora Bennani United States 17 440 0.7× 438 1.6× 167 1.5× 40 0.4× 39 0.4× 96 947
Wendy Osborne United Kingdom 14 342 0.6× 149 0.6× 39 0.3× 51 0.5× 47 0.4× 46 608

Countries citing papers authored by Ranjit Nair

Since Specialization
Citations

This map shows the geographic impact of Ranjit Nair's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranjit Nair with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranjit Nair more than expected).

Fields of papers citing papers by Ranjit Nair

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ranjit Nair. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranjit Nair. The network helps show where Ranjit Nair may publish in the future.

Co-authorship network of co-authors of Ranjit Nair

This figure shows the co-authorship network connecting the top 25 collaborators of Ranjit Nair. A scholar is included among the top collaborators of Ranjit Nair based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ranjit Nair. Ranjit Nair is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strati, Paolo, Lei Feng, Jason R. Westin, et al.. (2025). Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. Nature Communications. 16(1). 7300–7300.
2.
Fang, Penny, Sonal S. Noticewala, Susan Wu, et al.. (2024). Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?. Advances in Radiation Oncology. 9(12). 101650–101650.
3.
Iyer, Swaminathan P., Ranjit Nair, Neha Mehta–Shah, et al.. (2024). A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma. Blood. 144(Supplement 1). 4449–4449. 1 indexed citations
4.
Pradeep, Roshini, Ranjit Nair, Luis Malpica, et al.. (2024). Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS). Blood. 144(Supplement 1). 7776–7776.
5.
Westin, Jason R., Loretta J. Nastoupil, Ranjit Nair, et al.. (2024). Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7044–7044. 4 indexed citations
6.
Menon, Riju Ramachandran, et al.. (2024). Clinico-Pathological Study of Symptomatic Hyperparathyroidism: Is it a Different Phenotype Expression of Hyperparathyroidism?. Indian Journal of Otolaryngology and Head & Neck Surgery. 77(2). 680–685.
7.
Wu, Susan, Penny Fang, Kelsey L. Corrigan, et al.. (2024). Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung. Advances in Radiation Oncology. 9(12). 101648–101648. 1 indexed citations
8.
Corrigan, Kelsey L., Benjamin R. Schrank, Lewis Nasr, et al.. (2024). Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Frontiers in Oncology. 14. 1447020–1447020.
9.
Wu, Susan, Jie Xu, Penny Fang, et al.. (2024). Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder. International Journal of Dermatology. 64(2). 385–389.
10.
11.
Nair, Ranjit, Ryan Jacobs, Sumana Devata, et al.. (2023). HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY. Hematological Oncology. 41(S2). 127–129. 1 indexed citations
12.
13.
Wu, Susan, Penny Fang, Sairah Ahmed, et al.. (2023). Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Advances in Radiation Oncology. 8(6). 101279–101279. 4 indexed citations
14.
Corrigan, Kelsey L., Berthold Schrank, Lewis Nasr, et al.. (2023). Outcomes and Toxicities in Patients with Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract. International Journal of Radiation Oncology*Biology*Physics. 117(2). e460–e460.
15.
Nair, Ranjit, et al.. (2023). Capnocytophaga canimorsus Infection in a 38-Year-Old Male after a Dog Bite. SHILAP Revista de lepidopterología. 2023. 1–5.
16.
Jain, Preetesh, Rashmi Kanagal‐Shamanna, Shaojun Zhang, et al.. (2021). Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology. 96(5). E137–E140. 5 indexed citations
17.
Augustyn, Alexander, Jillian R. Gunther, Penny Fang, et al.. (2020). Radiation Therapy for Refractory High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. International Journal of Radiation Oncology*Biology*Physics. 108(3). S168–S168. 2 indexed citations
18.
Mamlouk, Omar, Ranjit Nair, Swaminathan P. Iyer, et al.. (2020). Safety of CAR T-cell therapy in kidney transplant recipients. Blood. 137(18). 2558–2562. 38 indexed citations
19.
Nair, Ranjit & Krina K. Patel. (2018). Emerging role of CAR T cell therapy in multiple myeloma. 1(3). e22–e22. 2 indexed citations
20.
Nair, Ranjit, et al.. (2016). ESTIMATION OF LIPID PROFILE IN VARIOUS GRADES OF NON ALCOHOLIC FATTY LIVER DISEASE DIAGNOSED ON ULTRASONOGRAPHY. International Journal of Pharma and Bio Sciences. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhitao Ying Breakdown of academic impact, for papers by Gloria Iacoboni Breakdown of academic impact, for papers by Hien Liu Breakdown of academic impact, for papers by Chaitra S. Ujjani Breakdown of academic impact, for papers by Shinichi Makita Breakdown of academic impact, for papers by Alison R. Sehgal Breakdown of academic impact, for papers by Houston Holmes Breakdown of academic impact, for papers by Quanshun Wang Breakdown of academic impact, for papers by N. Nora Bennani Breakdown of academic impact, for papers by Wendy Osborne
Rankless by CCL
2026